The complex world of polysaccharides edited by Desiree Nedra Karunaratne
Yüklə 27,58 Mb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- Document Outline
The Future of Synthetic Carbohydrate Vaccines: Immunological Studies on Streptococcus pneumoniae Type 14 629 [21] Bentley SD, Aanensen DM, Mavroidi A, Saunders D, Rabbinowitsch E, Collins M, Donohoe K, Harris D, Murphy L, Quail MA, Samuel G, Skovsted IC, Kaltoft MS, Barrell B, Reeves PR, Parkhill J, Spratt BG. Genetic analysis of the capsular biosynthetic locus from all 90 pneumococcal serotypes. PLoS.Genet. 2006;2(3):e31 [22] Mavroidi A, Aanensen DM, Godoy D, Skovsted IC, Kaltoft MS, Reeves PR, Bentley SD, Spratt BG. Genetic relatedness of the Streptococcus pneumoniae capsular biosynthetic loci. J.Bacteriol. 2007;189(21):7841-55. [23] Llull D, Garcia E, Lopez R. Tts, a processive beta-glucosyltransferase of Streptococcus pneumoniae, directs the synthesis of the branched type 37 capsular polysaccharide in Pneumococcus and other gram-positive species. J Biol.Chem 2001;276(24):21053-61. [24] Arrecubieta C, Lopez R, Garcia E. Type 3-specific synthase of Streptococcus pneumoniae (Cap3B) directs type 3 polysaccharide biosynthesis in Escherichia coli and in pneumococcal strains of different serotypes. J Exp.Med 1996;184(2):449-55. [25] Breukels MA, Rijkers GT, Voorhorst-Ogink MM, Zegers BJ, Sanders LA. Pneumococcal conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response in children with recurrent otitis media acuta. J.Infect.Dis. 1999;179(5):1152-6. [26] Rennels MB, Edwards KM, Keyserling HL, Reisinger KS, Hogerman DA, Madore DV, Chang I, Paradiso PR, Malinoski FJ, Kimura A. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM 197
in United States infants. Pediatrics 1998;101(4 Pt 1):604-11. [27] Prymula R, Kriz P, Kaliskova E, Pascal T, Poolman J, Schuerman L. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae- derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H.
[28] French N. Use of pneumococcal polysaccharide vaccines: no simple answers. J.Infect. 2003;46(2):78-86. [29] Ada G, Isaacs D. Carbohydrate-protein conjugate vaccines. Clin.Microbiol.Infect. 2003;9(2):79-85. [30] Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL. Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol. 2002;169(11):6149-53. [31] Choi YH, Roehrl MH, Kasper DL, Wang JY. A unique structural pattern shared by T- cell-activating and abscess-regulating zwitterionic polysaccharides. Biochemistry 2002;41(51):15144-51. [32] Karnezis TT, Smith A, Whittier S, Haddad J, Saiman L. Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine. PLoS One. 2009;4(6):e5965 [33] Valenzuela MT, de Quadros C. Antibiotic resistance in Latin America: a cause for alarm. Vaccine 2009;27 Suppl 3:C25-C28 [34] Vlieghe E, Phoba MF, Tamfun JJ, Jacobs J. Antibiotic resistance among bacterial pathogens in Central Africa: a review of the published literature between 1955 and 2008. Int.J Antimicrob.Agents 2009;34(4):295-303.
The Complex World of Polysaccharides 630 [35] Siira L, Rantala M, Jalava J, Hakanen AJ, Huovinen P, Kaijalainen T, Lyytikainen O, Virolainen A. Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006. Antimicrob.Agents Chemother. 2009;53(5):2066-73. [36] Vila-Corcoles A, Bejarano-Romero F, Salsench E, Ochoa-Gondar O, de DC, Gomez- Bertomeu F, Raga-Luria X, Cliville-Guasch X, Arija V. Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community- acquired pneumonia. BMC.Infect.Dis. 2009;9:36 [37] Imai S, Ito Y, Ishida T, Hirai T, Ito I, Maekawa K, Takakura S, Iinuma Y, Ichiyama S, Mishima M. High prevalence of multidrug-resistant Pneumococcal molecular epidemiology network clones among Streptococcus pneumoniae isolates from adult patients with community-acquired pneumonia in Japan. Clin.Microbiol.Infect. 2009; [38] Shibl AM. Distribution of serotypes and antibiotic resistance of invasive pneumococcal disease isolates among children aged 5 years and under in Saudi Arabia (2000-2004). Clin.Microbiol.Infect. 2008;14(9):876-9. [39] Yang F, Xu XG, Yang MJ, Zhang YY, Klugman KP, McGee L. Antimicrobial susceptibility and molecular epidemiology of Streptococcus pneumoniae isolated from Shanghai, China. Int.J.Antimicrob.Agents 2008;32(5):386-91. [40] Gottlieb T, Collignon PJ, Robson JM, Pearson JC, Bell JM. Prevalence of antimicrobial resistances in Streptococcus pneumoniae in Australia, 2005: report from the Australian Group on Antimicrobial Resistance. Commun.Dis.Intell. 2008;32(2):242-9. [41] Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine 2007;25(16):2963-73. [42] O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect.Dis. 2007;7(9):597-606. [43] Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007;297(16):1784-92. [44] Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect.Dis. 1983;148(1):131-7. [45] Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, Lindblad I, Sundelof B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351(9100):399-403. [46] Teshale EH, Hanson D, Flannery B, Phares C, Wolfe M, Schuchat A, Sullivan P. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV- infected adults in the United States, 1998--2003. Vaccine 2008;26(46):5830-4. [47] Veras MA, Enanoria WT, Castilho EA, Reingold AL. Effectiveness of the polysaccharide pneumococcal vaccine among HIV-infected persons in Brazil: a case control study. BMC.Infect.Dis. 2007;7:119 The Future of Synthetic Carbohydrate Vaccines: Immunological Studies on Streptococcus pneumoniae Type 14 631 [48] Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N.Engl.J.Med. 2003;348(18):1737-46. [49] Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009;123(6):e1103-e1110 [50] Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int.J.Infect.Dis. 2009;14(3):e197-209. [51] Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr.Infect.Dis.J. 2009;28(4 Suppl):S97-S108 [52] Bermal N, Szenborn L, Chrobot A, Alberto E, Lommel P, Gatchalian S, Dieussaert I, Schuerman L. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr.Infect.Dis.J. 2009;28(4 Suppl):S89-S96 [53] Meng C, Lin H, Huang J, Wang H, Cai Q, Fang L, Guo Y. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Microb.Pathog. 2009;47(3):151-6. [54] Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease . Lancet.Infect.Dis. 2004;4:144-54. [55] Xin W, Li Y, Mo H, Roland KL, Curtiss R, III. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect.Immun. 2009;77(10):4518-28. [56] Francis JP, Richmond PC, Pomat WS, Michael A, Keno H, Phuanukoonnon S, Nelson JB, Whinnen M, Heinrich T, Smith WA, Prescott SL, Holt PG, Siba PM, Lehmann D, van den Biggelaar AH. Maternal antibodies to pneumolysin, but not pneumococcal surface protein A, delay early pneumococcal carriage in high-risk Papua New Guinean infants. Clin.Vaccine Immunol. 2009;16(11):1633-8. [57] Ljutic B, Ochs M, Messham B, Ming M, Dookie A, Harper K, Ausar SF. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Vaccine 2012;Epub ahead of print [58] Pozsgay V. Recent developments in synthetic oligosaccharide-based bacterial vaccines. Curr.Top.Med Chem 2008;8(2):126-40. [59] Jansen WT, Snippe H. Short-chain oligosaccharide protein conjugates as experimental pneumococcal vaccines. Indian.J.Med.Res. 2004;119:7-12. [60] Benaissa-Trouw B, Lefeber DJ, Kamerling JP, Vliegenthart JF, Kraaijeveld K, Snippe H. Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide- CRM 197 conjugates The Complex World of Polysaccharides 632 induce protection against Streptococcus pneumoniae type 3 in mice. Infect.Immun. 2001;69(7):4698-701. [61] Plante OJ, Palmacci ER, Seeberger PH. Automated solid-phase synthesis of oligosaccharides. Science 2001;291(5508):1523-7. [62] Saksena R, Ma X, Wade TK, Kovác P, Wade WF. Length of the linker and the interval between immunizations influences the efficacy of Vibrio cholerae O1,Ogawa hexasaccharide neoglycoconjugates. FEMS Immunol.Med.Microbiol. 2006;47:116-28. [63] Saksena R, Ma X, Wade TK, Kovac P, Wade WF. Effect of saccharide length on the immunogenicity of neoglycoconjugates from synthetic fragments of the O-SP of Vibrio cholerae O1, serotype Ogawa. Carbohydr.Res. 2005;340:2256-69. [64] Bongat AF, Saksena R, Adamo R, Fujimoto Y, Shiokawa Z, Peterson DC, Fukase K, Vann WF, Kovac P. Multimeric bivalent immunogens from recombinant tetanus toxin H(C) fragment, synthetic hexasaccharides, and a glycopeptide adjuvant. Glycoconj.J. 2009;27(1):69-77. [65] Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Belot F, Cohen D, Sansonetti PJ, Mulard LA. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J.Immunol. 2009;182(4):2241-7. [66] Said HF, Phalipon A, Tanguy M, Guerreiro C, Belot F, Frisch B, Mulard LA, Schuber F. Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen. Vaccine 2009;27(39):5419-26. [67] Schofield L, Hewitt MC, Evans K, Siomos MA, Seeberger PH. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002;418(6899):785-9. [68] Jeon I, Lee D, Krauss IJ, Danishefsky SJ. A new model for the presentation of tumor- associated antigens and the quest for an anticancer vaccine: a solution to the synthesis challenge via ring-closing metathesis. J.Am.Chem.Soc. 2009;131(40):14337-44. [69] de Velasco EA, Verheul AF, Veeneman GH, Gomes LJ, van Boom JH, Verhoef J, Snippe H. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine 1993;11(14):1429-36. [70] Jansen WT, Verheul AFM, Veeneman GH, van Boom JH, Snippe H. Revised interpretation of the immunological results obtained with pneumococcal polysaccharide 17F derived synthetic di-, tri- and tetrasaccharide conjugates in mice and rabbits. Vaccine 2002;20:19-21. [71] de Velasco EA, Verheul AF, van Steijn AM, Dekker HA, Feldman RG, Fernandez IM, Kamerling JP, Vliegenthart JF, Verhoef J, Snippe H. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti- polysaccharide 23F IgG. Infect.Immun. 1994;62(3):799-808. [72] Jansen WT, Hogenboom S, Thijssen MJL, Kamerling JP, Vliegenthart JFG, Verhoef J, Snippe H, Verheul AFM. Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice. Infect.Immun. 2001;69(2):787-93. The Future of Synthetic Carbohydrate Vaccines: Immunological Studies on Streptococcus pneumoniae Type 14 633 [73] Safari D, Dekker HA, Joosten JA, Michalik D, de Souza AC, Adamo R, Lahmann M, Sundgren A, Oscarson S, Kamerling JP, Snippe H. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus
[74] Mawas F, Niggemann J, Jones C, Corbel MJ, Kamerling JP, Vliegenthart JFG. Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM 197 .
[75] Lindberg B, Lonngren J, Powel DA. Structural studies on the specific type 14 pneumococcal polysaccharide. Carbohydr.Res. 1977;58:177-86. [76] Joosten JA, Lazet BJ, Kamerling JP, Vliegenthart JF. Chemo-enzymatic synthesis of tetra- , penta-, and hexasaccharide fragments of the capsular polysaccharide of Streptococcus pneumoniae type 14. Carbohydr.Res 2003;338(23):2629-51. [77] Joosten JA, Kamerling JP, Vliegenthart JF. Chemo-enzymatic synthesis of a tetra- and octasaccharide fragment of the capsular polysaccharide of Streptococcus pneumoniae type 14. Carbohydr.Res 2003;338(23):2611-27. [78] Michalik D, Vliegenthart JFG, Kamerling JP. Chemoenzymic synthesis of oligosaccharide fragments of the capsular polysaccharide of Streptococcus pneumoniae type 14. J.Chem.Soc., Perkin Trans.1 2002;1973-81. [79] Sundgren A, Lahmann M, Oscarson S. Block synthesis of Streptococcus pneumoniae type 14 capsular polysaccharide structures. J.Carbohydr.Chem. 2005;24(4):379-91. [80] Safari D, Dekker HA, Rijkers G, van der Ende A, Kamerling JP, Snippe H. The immune response to group B streptococcus type III capsular polysaccharide is directed to the - Glc-GlcNAc-Gal- backbone epitope. Glycoconj.J. 2011;28:557-67. [81] Guttormsen HK, Baker CJ, Nahm MH, Paoletti LC, Zughaier SM, Edwards MS, Kasper DL. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14. Infect.Immun. 2002;70(4):1724-38. [82] Kadirvelraj R, Gonzalez-Quteirino J, Foley BL, Beckham ML, Jennings HJ, Foote S, Ford MG, Woods RJ. Understanding the bacterial polysaccharide antigenicity of Streptococcus agalactiae versus Streptococcus pneumoniae. Proc.Natl.Acad.Sci.USA 2007;103(21):8149-54. [83] Jennings HJ, Lugowski C, Kasper DL. Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry 1981;20(16):4511-8. [84] Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, Peters HV, Knutsen B, Hickel J, Parkinson AJ. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. Clin.Infect.Dis. 2009;49(2):241-8. [85] Safari D, Dekker HA, de Jong B, Rijkers G, Kamerling JP, Snippe H. Antibody- and cell- mediated immune responses to a synthetic oligosaccharide conjugate vaccine after booster immunization. Vaccine 2011;29(38):6498-504. [86] Lefeber DJ, Benaissa-Trouw B, Vliegenthart JFG, Kamerling JP, Jansen WTM, Kraaijeveld K, Snippe H. Th1-directing adjuvants increase the immunogenicity of
The Complex World of Polysaccharides 634 oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect.Immun. 2003;71(12):6915-20. [87] Safari D, Dekker HA, Rijkers G, Snippe H. Codelivery of adjuvants at the primary immunization site is essential for evoking a robust immune response to neoglycoconjugates. Vaccine 2011;29(4):849-54. Document Outline
Yüklə 27,58 Mb. Dostları ilə paylaş:
|